MDGL
Price
$294.40
Change
+$0.24 (+0.08%)
Updated
Jul 29 closing price
Capitalization
6.54B
6 days until earnings call
TRAW
Price
$1.56
Change
-$0.06 (-3.70%)
Updated
Jul 29 closing price
Capitalization
8.79M
Interact to see
Advertisement

MDGL vs TRAW

Header iconMDGL vs TRAW Comparison
Open Charts MDGL vs TRAWBanner chart's image
Madrigal Pharmaceuticals
Price$294.40
Change+$0.24 (+0.08%)
Volume$259.85K
Capitalization6.54B
Traws Pharma
Price$1.56
Change-$0.06 (-3.70%)
Volume$36K
Capitalization8.79M
MDGL vs TRAW Comparison Chart in %
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRAW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. TRAW commentary
Jul 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a StrongBuy and TRAW is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 30, 2025
Stock price -- (MDGL: $294.40 vs. TRAW: $1.58)
Brand notoriety: MDGL and TRAW are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 83% vs. TRAW: 2%
Market capitalization -- MDGL: $6.54B vs. TRAW: $8.79M
MDGL [@Biotechnology] is valued at $6.54B. TRAW’s [@Biotechnology] market capitalization is $8.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $315.74B to $0. The average market capitalization across the [@Biotechnology] industry is $2.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whileTRAW’s FA Score has 1 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • TRAW’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than TRAW.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 5 TA indicator(s) are bullish while TRAW’s TA Score has 5 bullish TA indicator(s).

  • MDGL’s TA Score: 5 bullish, 6 bearish.
  • TRAW’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, TRAW is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а -6.06% price change this week, while TRAW (@Biotechnology) price change was -2.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.71%. For the same industry, the average monthly price growth was +15.03%, and the average quarterly price growth was +41.55%.

Reported Earning Dates

MDGL is expected to report earnings on Oct 30, 2025.

TRAW is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+2.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.54B) has a higher market cap than TRAW($8.79M). MDGL YTD gains are higher at: -4.592 vs. TRAW (-82.207). TRAW has higher annual earnings (EBITDA): -24.89M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. TRAW (15.9M). MDGL has higher revenues than TRAW: MDGL (317M) vs TRAW (227K).
MDGLTRAWMDGL / TRAW
Capitalization6.54B8.79M74,352%
EBITDA-376.15M-24.89M1,511%
Gain YTD-4.592-82.2076%
P/E RatioN/AN/A-
Revenue317M227K139,648%
Total Cash843M15.9M5,302%
Total Debt120MN/A-
FUNDAMENTALS RATINGS
MDGL vs TRAW: Fundamental Ratings
MDGL
TRAW
OUTLOOK RATING
1..100
6210
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
44100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
6265
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRAW's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for MDGL (61) in the Pharmaceuticals Other industry. This means that TRAW’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for TRAW (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than TRAW’s over the last 12 months.

MDGL's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as TRAW (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to TRAW’s over the last 12 months.

MDGL's Price Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as TRAW (65) in the Biotechnology industry. This means that MDGL’s stock grew similarly to TRAW’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as TRAW (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to TRAW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLTRAW
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 16 days ago
77%
Bullish Trend 13 days ago
75%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
72%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRAW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEGOX33.34N/A
N/A
First Eagle Gold C
FAIRX33.09N/A
N/A
Fairholme
RAFBX37.27N/A
N/A
American Funds AMCAP R2
MFVFX14.41N/A
N/A
MassMutual Equity Opports R4
VYRDX16.84N/A
N/A
VY® Columbia Small Cap Value II R6

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+0.08%
KANT - MDGL
62%
Loosely correlated
N/A
ALXO - MDGL
56%
Loosely correlated
-7.17%
NAGE - MDGL
46%
Loosely correlated
-0.31%
IPHA - MDGL
44%
Loosely correlated
-2.73%
RNAC - MDGL
43%
Loosely correlated
-2.19%
More